Terapie
komórkami macierzystymi
Terapie komórkami macierzystymi
Celem bankowania komórek macierzystych jest ich późniejsze wykorzystanie w terapii. Krew pępowinowa została zastosowana po raz pierwszy w 1988 roku, a od tego czasu – zgodnie z dostępnymi danymi – komórki macierzyste zostały użyte na świecie ponad 85 000 razy (łącznie ze statystykami z Chin).
Grupa FamiCord przechowuje ponad 1 000 000 porcji komórek różnych typów i dostarczyła komórki macierzyste do zastosowań klinicznych dla ponad 7000 pacjentów. Dostarczamy komórki do standardowych przeszczepień (z krwi pępowinowej, szpiku kostnego i mobilizowanej krwi obwodowej) oraz do terapii komórkowych. Ponadto wytwarzamy produkty komórkowe w standardzie GMP (ang. Good Manufacturing Practice) do badań klinicznych.
Komórki macierzyste pochodzące z naszych laboratoriów były wykorzystywane w leczeniu pacjentów z chorobami i wskazaniami z różnych obszarów terapeutycznych – m.in. hematologii, neurologii, okulistyki, ortopedii i dermatologii.
Sprawdź pełną listę pacjentów, którzy otrzymali terapię komórkami macierzystymi pochodzącymi z laboratoriów Grupy FamiCord.
Data aktualizacji: 06.2026
Lista pacjentów, którzy otrzymali komórki macierzyste z laboratoriów Grupy FamiCord
| Lp. | Źródło | Typ źródła | Wskazanie | Obszar medycyny | Rok podania | Terapia | Kraj | Wiek odbiorcy |
|---|---|---|---|---|---|---|---|---|
| 3001 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 52 |
| 3002 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 66 |
| 3003 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 39 |
| 3004 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 53 |
| 3005 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 65 |
| 3006 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 58 |
| 3007 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 66 |
| 3008 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 71 |
| 3009 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 67 |
| 3010 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 67 |
| 3011 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 40 |
| 3012 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 54 |
| 3013 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 57 |
| 3014 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 70 |
| 3015 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 40 |
| 3016 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 71 |
| 3017 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 28 |
| 3018 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 88 |
| 3019 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 68 |
| 3020 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 71 |
| 3021 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 61 |
| 3022 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 62 |
| 3023 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 54 |
| 3024 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 71 |
| 3025 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 48 |
| 3026 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 1 |
| 3027 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 67 |
| 3028 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 66 |
| 3029 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 56 |
| 3030 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 40 |
| 3031 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 36 |
| 3032 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 37 |
| 3033 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 26 |
| 3034 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 20 |
| 3035 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 74 |
| 3036 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 55 |
| 3037 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 56 |
| 3038 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 48 |
| 3039 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 13 |
| 3040 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 65 |
| 3041 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 48 |
| 3042 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 67 |
| 3043 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 52 |
| 3044 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 50 |
| 3045 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 61 |
| 3046 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 35 |
| 3047 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 61 |
| 3048 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 47 |
| 3049 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 34 |
| 3050 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 62 |
| 3051 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 60 |
| 3052 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 62 |
| 3053 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 64 |
| 3054 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 29 |
| 3055 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 63 |
| 3056 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 1 |
| 3057 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 39 |
| 3058 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 43 |
| 3059 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 63 |
| 3060 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 21 |
| 3061 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Germany | 58 |
| 3062 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Germany | 45 |
| 3063 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Germany | 63 |
| 3064 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Germany | 54 |
| 3065 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Germany | 48 |
| 3066 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Germany | 61 |
| 3067 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Germany | 27 |
| 3068 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Germany | 61 |
| 3069 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Germany | 66 |
| 3070 | Apheresis | Allogeneic | Acute Myeloid Leukemia – Relapse | Hematology | 2022 | Standard Therapy | Germany | 47 |
| 3071 | Apheresis | Allogeneic | Acute Myeloid Leukemia; Myelodysplastic Syndrome | Hematology | 2022 | Standard Therapy | Germany | 55 |
| 3072 | Apheresis | Allogeneic | Acute Promyelocytic Leukemia | Hematology | 2022 | Standard Therapy | Poland | 49 |
| 3073 | Apheresis | Allogeneic | Acute Promyelocytic Leukemia | Hematology | 2022 | Standard Therapy | Poland | 40 |
| 3074 | Apheresis | Allogeneic | Alk-Positive Anaplastic T-Cell Lymphoma | Hematology | 2022 | Standard Therapy | Poland | 15 |
| 3075 | Apheresis | Autologous | Anaplastic Large Cell Lymphoma | Hematology | 2022 | Standard Therapy | Germany | 22 |
| 3076 | Apheresis | Allogeneic | Aplastic Anemia | Hematology | 2022 | Standard Therapy | Poland | 22 |
| 3077 | Apheresis | Allogeneic | Aplastic Anemia | Hematology | 2022 | Standard Therapy | Poland | 16 |
| 3078 | Apheresis | Allogeneic | Aplastic Anemia | Hematology | 2022 | Standard Therapy | Poland | 17 |
| 3079 | Apheresis | Allogeneic | Aplastic Anemia | Hematology | 2022 | Standard Therapy | Germany | 67 |
| 3080 | Apheresis | Allogeneic | Atypical Chronic Myeloid Leukemia | Hematology | 2022 | Standard Therapy | Poland | 62 |
| 3081 | Apheresis | Allogeneic | B-Cell Acute Lymphoblastic Leukemia | Hematology | 2022 | Standard Therapy | Poland | 46 |
| 3082 | Apheresis | Allogeneic | B-Cell Acute Lymphoblastic Leukemia | Hematology | 2022 | Standard Therapy | Poland | 18 |
| 3083 | Apheresis | Allogeneic | B-Cell Acute Lymphoblastic Leukemia | Hematology | 2022 | Standard Therapy | Germany | 54 |
| 3084 | Apheresis | Allogeneic | Beta Thalassemia Major | Hematology | 2022 | Standard Therapy | Poland | 11 |
| 3085 | Apheresis | Allogeneic | C-All Rez (Acute Lymphoblastic Leukemia) | Hematology | 2022 | Standard Therapy | Poland | 66 |
| 3086 | Apheresis | Allogeneic | C-All Rez (Acute Lymphoblastic Leukemia) | Hematology | 2022 | Standard Therapy | Poland | 5 |
| 3087 | Apheresis | Allogeneic | Chronic Granulomatous Disease | Hematology | 2022 | Standard Therapy | Poland | 3 |
| 3088 | Apheresis | Allogeneic | Chronic Granulomatous Disease | Hematology | 2022 | Standard Therapy | Poland | 3 |
| 3089 | Apheresis | Allogeneic | Chronic Granulomatous Disease | Hematology | 2022 | Standard Therapy | Poland | 5 |
| 3090 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2022 | Standard Therapy | Poland | 63 |
| 3091 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2022 | Standard Therapy | Poland | 59 |
| 3092 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2022 | Standard Therapy | Germany | 58 |
| 3093 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia Richter Transformation 7/22 | Hematology | 2022 | Standard Therapy | Poland | 44 |
| 3094 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2022 | Standard Therapy | Poland | 64 |
| 3095 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2022 | Standard Therapy | Poland | 67 |
| 3096 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2022 | Standard Therapy | Poland | 63 |
| 3097 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2022 | Standard Therapy | Poland | 59 |
| 3098 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2022 | Standard Therapy | Poland | 64 |
| 3099 | Apheresis | Allogeneic | Chronic Myelogenous Leukemia | Hematology | 2022 | Standard Therapy | Poland | 60 |
| 3100 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2022 | Standard Therapy | Poland | 70 |